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A new method for identifying 
causal genes of schizophrenia and 
anti-tuberculosis drug-induced 
hepatotoxicity
Tao Huang1,2, Cheng-Lin Liu3, Lin-Lin Li1, Mei-Hong Cai1, Wen-Zhong Chen4, Yi-Feng Xu1,4, 
Paul F. O’Reilly5, Lei Cai1,4 & Lin He1,4
Schizophrenia (SCZ) may cause tuberculosis, the treatments for which can induce anti-tuberculosis 
drug-induced hepatotoxicity (ATDH) and SCZ-like disorders. To date, the causal genes of both SCZ 
and ATDH are unknown. To identify them, we proposed a new network-based method by integrating 
network random walk with restart algorithm, gene set enrichment analysis, and hypergeometric test; 
using this method, we identified 500 common causal genes. For gene validation, we created a regularly 
updated online database ATDH-SCZgenes and conducted a systematic meta-analysis of the association 
of each gene with either disease. Till now, only GSTM1 and GSTT1 have been well studied with respect 
to both diseases; and a total of 23 high-quality association studies were collected for the current 
meta-analysis validation. Finally, the GSTM1 present genotype was confirmed to be significantly 
associated with both ATDH [Odds Ratio (OR): 0.71, 95% confidence interval (CI): 0.56–0.90, P = 0.005] 
and SCZ (OR: 0.78, 95% CI: 0.66–0.92, P = 0.004) according to the random-effect model. Furthermore, 
these significant results were supported by “moderate” evidence according to the Venice criteria. Our 
findings indicate that GSTM1 may be a causal gene of both ATDH and SCZ, although further validation 
pertaining to other genes, such as CYP2E1 or DRD2, is necessary.
Schizophrenia (SCZ) is a severe, disabling, and chronic mental disorder that affects approximately 1% of the gen-
eral population1. Recent research has identified a potential link between SCZ and an increased risk of contacting 
tuberculosis (TB)2, a devastating infectious disease that remains the major leading cause of death worldwide3. 
The most commonly used anti-TB drugs, although effective4, can induce anti-tuberculosis drug-induced hepato-
toxicity(ATDH), the most frequent and serious side effect of TB therapy. ATDH, also known as anti-tuberculosis 
drug-induced liver injury (ATDILI)5, is caused by the drugs’ reactive metabolites rather than direct toxicity and 
can impede scheduled treatment, leading to increased complications morbidity and reduced treatment com-
pliance6. Moreover, anti-TB drugs can also induce or cause relapse of psychiatric disorders, including SCZ-like 
disorders7–9.
Few previous studies have addressed the potential relationship between ATDH and SCZ, which belong to 
two different disease categories. Although we previously proposed that GST genes represent a link between 
ATDILI and SCZ10, the molecular basis underlying the connection between ATDH and SCZ is currently unclear. 
Therefore, identification of common causal genes underlying both diseases would greatly benefit our understand-
ing of the relationship between ATDH and SCZ. In addition, knowledge about this link would also be beneficial to 
people at risk of developing SCZ and/or TB, particularly in the context of anti-TB drug therapy.
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The identification of all genes related to both ATDH and SCZ and subsequent evaluation of their biological 
roles in vitro and in vivo comprise one possible strategy for elucidating their molecular mechanisms. However, 
this approach represents an insurmountable challenge for the large-scale identification of disease-related genes. 
Therefore, we propose a new network-based pipeline for analyzing the connection between these two diseases 
and prioritizing the identification of potential common key causal genes that influence the development of these 
two diseases by integrating network random walk with restart (RWR) algorithm, gene set enrichment analysis 
(GSEA), and hypergeometric test.
Network-based analyses, which assume that neighboring genes have similar effects, have demonstrated great 
promise for the identification of causal factors and key driver genes associated with a particular disease11,12. 
However, in our proposed novel network-based analysis pipeline to identify candidate key causal genes of both 
ATDH and SCZ, we first applied RWR to expand the known ATDH- and SCZ-related genes, for which little over-
lap had previously been detected. RWR simulates a random walker on the network starting from seed genes and 
moving toward randomly chosen interacting neighbors at each step13. After walking many steps, the probability 
of moving to each node on the network tends to stabilize, and novel candidate disease genes can be identified. A 
GSEA like method was then adopted to find the peak of a running sum curve, which indicates the stop point for 
RWR expansion. RWR expansion identified many common genes shared by the expanded ATDH and SCZ gene 
lists. Subsequently, a hypergeometric test was used to test all genes on the network to determine whether neigh-
boring genes were also significantly enriched among the genes common to both ATDH and SCZ. A positive result 
indicated a key gene driver that could affect both ATDH- and SCZ- related genes.
Additionally, we conducted a field synopsis or systemic meta-analysis of published studies to assess whether 
these key gene drivers represent causal genes common to both ATDH and SCZ by validating the associations 
between gene polymorphisms and ATDH or SCZ. Systemic meta-analysis is a reliable approach that involves 
pooling both statistically significant and non-significant results from individual studies to generate a more precise 
conclusion14–16. In the end, 500 candidate genes were detected as common causal ones for both ATDH and SCZ 
using our new method. Among these genes, the glutathione S-transferase Mu-1 gene (GSTM1) was validated as a 
causal factor of these two diseases. Furthermore, we continue to update the validation of other genes in our newly 
created online database ATDH-SCZgenes (http://www.bio-x.cn/ATDH-SCZgenes.html).
Results
Identification of causal genes for both ATDH and SCZ. Five known ATDH/ATDILI-related genes 
and 1, 305 known SCZ-related genes were collected from GenBank. The human STRING network database was 
then used to map five and 1, 079 genes were mapped on the network for ATDH and SCZ, respectively. Using these 
mapped genes, we predicted 3, 045 and 1, 458 possible ATDH- and SCZ-related genes, respectively, with potential 
effects on known disease-related genes. Among these, we identified 878 overlapping genes between the expanded 
ATDH and SCZ gene lists, which are shown in Supplementary Table S3. Furthermore, 500 genes with significant 
false discovery rate (FDR-) corrected hypergeometric test P values (< 10−8) were identified as causal factors for 
both ATDH and SCZ (Supplementary Table S4).
To validate these 500 genes as common causal factors for both ATDH and SCZ, we created a regularly updated 
online database ATDH-SCZgenes (www.bio-x.cn/ATDH-SCZgenes.html) and conducted a field synopsis/sys-
temic meta-analysis to analyze associations of polymorphisms in each potential gene with ATDH or SCZ. During 
validation, GWAS data were firstly collected, and then, candidate gene association studies data were collected. To 
date, no GWAS for ATDH have been reported yet. Among these genes, only GSTM1, CYP2E1 and glutathione 
S-transferase theta-1(GSTT1) (P = 5.61E-22, 4.54E-18 and 3.87E-09, respectively, Table 1) have been reported 
to associate with both ATDH and SCZ; all other genes were reported to associate with at most either disease 
alone. Genes with significant effects only on SCZ, which were obtained from the SzGene database17 or a systemic 
meta-analysis of genome wide association study (GWAS) data provided by Ricopili18, are listed in Supplementary 
Table S5; in the future, association of these genes with ATDH will require testing.
Characteristics of the included studies. A flow diagram summarizing the study selection process is 
shown in Supplementary Fig. 1. A total of 33 and 24 potentially relevant studies regarding the association between 
CYP2E1/GSTM1/GSTT1 polymorphisms and the respective risks of ATDH and SCZ were identified after an 
initial screening based on the titles and/or abstracts of the candidate articles. After the second screening, 699 
cases and 2,546 controls from fifteen studies of CYP2E1 and ATDH, 679 cases and 2,289 controls from fourteen 
studies of GSTM1 and ATDH, 592 cases and 2,569 controls from fourteen studied of GSTT1 and ATDH, one 
case-control study of CYP2E1 and SCZ, 1,469 cases and 1,605 controls from seven studies of GSTM1 and SCZ, 
and 936 cases and 971 controls from five studies of GSTT1 and SCZ were identified. The detailed characteristics 
of each study were listed in Supplementary Table S6. All studies confirmed the same complete loss of GSTM1 or 
GSTT1 mutation. Because the association studies involving CYP2E1did not meet the fifth inclusion criterion (i. e., 
Genes
Number of 
neighbors
Number of 
neighbors that are 
common disease
FDR 
corrected P
GSTM1 48 33 5.61E-22
CYP2E1 70 36 4.54E-18
GSTT1 13 11 3.87E-09
Table 1.  The shared key causal genes for ATDH and SCZ.
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at least three studies regarding the association of each gene with either disease), studies involving this gene were 
omitted (detailed information about CYPE2E1 can be obtained from the online database). The genotype distri-
butions of the cases and controls from all studies involving GSTM1 or GSTT1 in the context of ATDH and SCZ 
are presented in Tables 2 and 3, respectively. The null genotype refers to homozygous gene loss, which indicates a 
loss of gene function, and the present genotype includes both heterozygous gene loss and homozygous complete 
gene presence.
Association of GST polymorphisms with ATDH. Evaluations of the associations between GSTM1/
GSTT1 polymorphisms and the risk of ATDH are summarized in Fig. 1. Significant heterogeneity in the effects 
of these polymorphisms was observed for GSTM1, but not for GSTT1 [P = 0.088 and I2 = 36%, 95% confidence 
interval (CI): 0-0.662 for GSTM1, P = 0.12 and I2 = 32%, 95% CI: 0-0.61 for GSTT1]. Because fewer than 20 
studies were included in the meta-analysis, the random-effect model was used for both GSTM1 and GSTT1. The 
frequencies of GSTM1/GSTT1 null genotypes among the cases were higher than those among the controls (cases 
vs. controls: 51.25% vs. 42.85% for GSTM1, and 33.61% vs. 31.88% for GSTT1). The GSTM1 present genotype 
was significantly associated with a decreased risk of ATDH [odd ratio (OR): 0.71, 95% CI: 0.56–0.90, P = 0.005] 
(Fig. 1A). No significant association between the GSTT1 present genotype and ATDH was observed (OR 0.83, 
95% CI: 0.63–1.09, P = 0.18; Fig. 1B).
Association of GST polymorphisms with SCZ. The combined results regarding the association between 
GSTM1/GSTT1 polymorphisms and the risk of SCZ are presented in Fig. 2. Significant effect heterogeneity was 
observed in relation to GSTT1, but not for GSTM1 (P = 0.27 and I2 = 21%, 95% CI: 0–0.642 for GSTM1, P = 0.004 
and I2 = 74%, 95% CI: 0.351–0.895 for GSTT1). Again, the random-effect model was used for both genes because 
of the small number of studies. The GSTM1 null genotype and the GSTT1 present genotype were more frequent 
First author, year Ethnicity
Cases Controls
P*Null Present Total Null Present Total
GSTM1 polymorphism
 Chatterjee, 2009 Indian 25 26 51 49 51 100 0.998
 Gupta, 2013 Indian 21 29 50 61 185 246 0.013
 Huang, 2007 Chinese 42 21 63 29 34 63 0.02
 Kim, 2010 Korea 26 31 57 104 86 190 0.226
 Leiro, 2008 Spanish 12 23 35 25 35 60 0.477
 Liu, 2014 Chinese 14 6 20 96 47 143 0.798
 Monteiro, 2012 Brazilian 21 38 59 34 84 118 0.358
 Rana, 2014 Indian 19 36 55 42 203 245 0.004
 Roy, 2001 Indian 17 16 33 8 25 33 0.022
 Singla, 2013 Indian 10 7 17 165 226 391 0.175
 Sotsuka, 2011 Japanese 12 8 20 50 42 92 0.645
 Tang, 2012 Chinese 55 34 89 203 153 356 0.414
 Teixeira, 2011 Brazilian 11 15 26 61 80 141 0.928
 Wang, 2010 Chinese 63 41 104 54 57 111 0.079
 Total 348 331 679 981 1308 2289
GSTT1 polymorphism
 Chatterjee, 2009 Indian 3 48 51 3 97 100 0.391
 Gupta, 2013 Indian 11 39 50 30 216 246 0.067
 Huang, 2007 Chinese 24 39 63 25 38 63 0.855
 Kim, 2010 Korea 34 23 57 103 87 190 0.469
 Leiro, 2008 Spanish 17 18 35 16 44 60 0.031
 Liu, 2014 Chinese 13 7 20 97 46 143 0.8
 Monteiro, 2012 Brazilian 11 48 59 28 90 118 0.442
 Rana, 2014 Indian 14 41 55 79 164 245 0.308
 Roy, 2001 Indian 5 28 33 1 32 33 0.087
 Singla, 2013 Indian 8 9 17 102 289 391 0.056
 Sotsuka, 2011 Japanese 7 13 20 40 52 92 0.486
 Tang, 2012 Chinese 40 49 89 164 192 356 0.849
 Teixeira, 2011 Brazilian 4 22 26 27 114 141 0.65
 Wang, 2010 Chinese 40 49 89 164 192 356 0.849
 Total 231 433 664 879 1653 2534
Table 2.  Genotype distributions of GSTM1/T1 polymorphisms among ATDH as cases and non-ATDH as 
controls. The null genotype means homozygous loss of genes, and the present genotype includes heterozygous 
loss of genes and homozygous complete genes. *P value for chi-square test of genotype distribution.
www.nature.com/scientificreports/
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among cases than among controls (cases vs. controls: 56.71% vs. 51.15% for the GSTM1 null genotype, 31.2% 
vs. 38.62% for the GSTT1 null genotype). Statistically significant association were observed between the GSTM1 
present genotype and a decreased risk of SCZ (OR 0.78, 95% CI: 0.66–0.92, P = 0.004; Fig. 2A), and between the 
GSTT1 present genotype and SCZ (OR 1.37, 95% CI: 0. 93–2.03, P = 0.11; Fig. 2B).
Sensitivity analyses and publication bias. A sensitivity analysis was conducted via sequential analysis 
after omitting one study at a time to assess the effects of individual studies on the overall meta-analysis estimate. 
When one study was excluded, the P values for overall effects ranged from 0.004 to 3.97E-5 and from 0.17 to 0.68, 
in the GSTM1/GSTT1 and ATDH fixed-effect model analyses, respectively; for the fixed-effect model analyses of 
GSTM1/GSTT1 and SCZ, the respective P values for overall effects ranged from 0.001 to 0.015 and from 0.005 to 
0.32. These values indicate the stability of these analytical results.
Furthermore, Harbord’s test indicated no significant publication bias in the overall meta-analysis except 
for studies of the association between GSTT1 and ATDH and the association of GSTM1and SCZ (P = 0.56 for 
GSTM1 vs. ATDH; P = 0.08 for GSTT1 vs. ATDH; P = 0.0637for GSTM1 vs.SCZ; P = 0.91 for GSTT1 vs. SCZ).
Credibility of meta-analysis results. The Power and Sample Size Program19 indicated that the total sam-
ple size had a power > 90% to detect significant associations of the GSTM1 present genotype with ATDH and SCZ 
First author, year Ethnicity
Cases Controls
P*Null Present Total Null Present Total
GSTM1 polymorphism
 Gravina, 2011 Italian 82 56 138 70 63 133 0.26
 Harada, 2001 Japanese 57 30 87 87 89 176 0.014
 Matsuzawa, 2008 Japanese 129 85 214 119 101 220 0.193
 Pae, 2004 Korean 70 41 111 61 69 130 0.012
 Raffa, 2013 Tunisian 79 59 138 63 60 123 0.329
 Saruwatari, 2013 Japanese 77 77 154 99 104 203 0.818
 Watanabe, 2010 Japanese 339 288 627 322 298 620 0.451
 Total 833 636 1469 821 784 1605
GSTT1 polymorphism
 Gravina, 2011 Italian 25 113 138 30 103 133 0.364
 Matsuzawa, 2008 Japanese 88 126 214 80 140 220 0.309
 Raffa, 2013 Tunisian 59 79 138 67 56 123 0.059
 Saadat, 2007 Iranian 52 240 292 99 193 292 9E-06
 Saruwatari, 2013 Japanese 68 86 154 99 104 203 0.387
 Total 292 644 936 375 596 971
Table 3.  Genotype distributions of GSTM1/T1 polymorphisms among SCZ and healthy control. The null 
genotype means homozygous loss of genes, and the present genotype includes heterozygous loss of genes and 
homozygous complete genes. *P value for chi-square test of genotype distribution.
Figure 1. Forest plots from meta-analysis of GSTM1/GSTT1 polymorphisms and ATDH. (A) Summary of 
the ORs and corresponding 95% CIs for the GSTM1 present genotype; (B) summary of the ORs and 95% CIs for 
the GSTT1 present genotype.
www.nature.com/scientificreports/
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at ORs of 0.71 and 0.78, respectively. Furthermore, the respective false-positive reporting probabilities (FPRP) at 
a P value < 0.05 for the associations of GSTM1 present genotype with ATDH and SCZ were 0.088 and 0.063, with 
respective ORs of 0.6 and 0.7 (Supplementary Table S7).
Moreover, the strict inclusion criteria of this meta-analysis had addressed the genotyping quality. For the 
meta-analysis of ATDH studies, the nminor for the GSTM1 null genotype was 1,329, and a grade of A was given. 
The I2 was 36% and a grade of B was given. After excluding a 2001 study by Roy20, a significant association 
remained between the GSTM1 present genotype and ATDH (P = 0.01), with a Harbord’s test P value of 0.86820. 
For the meta-analysis of SCZ studies, the nminor for the GSTM1 present genotype was 1,654, and a grade of A was 
given. A grade of A was also given for the I2 of 21%. After excluding 2001 study by Harada21, a significant associa-
tion remained between the GSTM1 present genotype and SCZ (P = 0.014), with a Harbord’s test P value of 0.138. 
According to the Venice criteria22,23, “moderate” cumulative evidence supported significant associations of the 
GSTM1 present genotype with both ATDH and SCZ.
Discussion
As noted previously, ATDH can impede TB treatment schedules and thereby increase complications morbidity6. 
Psychiatric disorders has also been reported to represent an additional adverse effect of anti-TB drugs5,7. SCZ is 
a severe psychiatric disorder, given that TB and SCZ are frequent co-morbid conditions2,7, understanding the 
molecular basis for the relationship between ATDH and SCZ would not only facilitate personalized medicine by 
allowing physicians to identify potential exacerbation of SCZ and induction of ATDH patients, but could help 
to elucidate the molecular mechanisms common to both diseases. Previously, however, the relationship between 
ATDH and SCZ has been unclear, and knowledge about common biological determinants between these condi-
tions has yet to emerge.
Previously, we proposed that GST genes might serve as a link between ATDILI and SCZ10. To provide a 
global perspective of the hidden molecular basis for the connection between ATDH and SCZ, we proposed a 
protein-protein interaction (PPI) network-based analysis pipeline that would prioritize possible key drivers that 
might affect both ATDH and SCZ by extending ATDH-related or SCZ-related gene sets to neighboring genes and 
identifying key causal genes that overlap in these extended gene sets. Although a direct overlap of known gene 
sets is the most intuitive way of exploring a genetic association of two diseases, such a direct overlap would fail 
to reflect the complexity of the intertwined regulation between these two diseases. Moreover, because the known 
disease gene sets are incomplete, the lacking genes could lead to a naive comparison. In contrast, in our proposed 
method, we qualitatively analyzed the potential nature of a gene as a key driver of two diseases using the hyper-
geometric test. Furthermore, identified candidate key drivers were ranked according to P value significance and 
network microenvironments (i.e., potential interaction neighbors). The ability to reconstruct potential causal 
signaling will facilitate further molecular biology studies.
In addition, identified key drivers can provide clues about therapeutic interventions that affect genes from 
both diseases. We note that EnrichNet use similar methods to determine the enrichment of one gene set into a 
particular pathway or other signatures24; these include employing information from the PPI network and extend-
ing the seed genes to neighboring gene using the RWR method. However, EnrichNet measures the significance of 
a relationship between a series of extended genes and a particular pathway according to different RWR distance 
cutoffs, whereas our method determines the best RWR distance cutoff. Specifically, we adopted the concept of 
the leading-edge subset used in GSEA, which is a sorted the neighbor gene lists based on RWR distances, and 
labeled the seed genes as positive and other genes as negative. Using our method, the peak at which the running 
sum maximally deviates from zero determines the best RWR distance cutoff; subsequently, we can determine 
the best extended genes for either disease and study the overlaps to identify candidate key causal genes using 
the hypergeometric test. Therefore, EnrichNet and our analysis pipeline use similar methods in different ways to 
address different problems.
Figure 2. Forest plots from meta-analysis of GSTM1/GSTT1 polymorphisms and SCZ. (A) Summary of the 
ORs and corresponding 95% CIs for the GSTM1 present genotype; (B) summary of ORs and 95% CIs for the 
GSTT1 present genotype.
www.nature.com/scientificreports/
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In the present study, we used our novel pipeline analysis to identify 500 genes with a P < 10−8 as possible 
causal genetic factors shared by ATDH and SCZ. Given the nature of ATDH, however, it is difficult to collect 
a sufficient number of patients with both ATDH and SCZ in the absence of other comorbidities. Because sys-
temic meta-analysis is considered as a powerful tool for the identification of genes associated with a certain 
disease, we have created and regularly updated the online database ATDH-SCZgenes (http://www.bio-x.cn/
ATDH-SCZgenes.html) to analyze and validate the association between candidate genes and both diseases.
Among the 500 evaluated candidate genes, to date, only GSTM1, CYP2E1 and GSTT1 were found to associ-
ate with both ATDH and SCZ; all others associated with neither or only one of the diseases. In the analysis of 
CYP2E1and ATDH, a pooled OR of 1.2(95% CI: 0.85–1.68) was determined for the rs2031920 (− 1053C > T) 
polymorphism, whereas a fixed-effect model yielded a pooled OR of 1.3(95% CI: 1.06–1.59). Only one previous 
study has evaluated and identified a positive association between CYP2E1 and SCZ. In contrast, the SzGene data-
base17 and a systemic meta-analysis of SCZ GWAS data18 failed to corroborate that significant association, but 
consistently supported DRD2 to be significantly associated with SCZ. DRD2 has been reported as a prominent 
genetic risk factor for susceptibility to severe alcoholism25, which is associated with liver damage. Further valida-
tion of the associations of these genes with ATDH and SCZ is needed in the future.
Through a systemic meta-analysis, we validated a significant association of the GSTM1 null genotype with 
increased risks of both ATDH and SCZ, and these significant results were supported by “moderate” evidence 
according to the Venice criteria22, suggesting that GSTM1 may be a causal factor shared by both ATDH and SCZ.
ATDH has been widely suggested to be a Glutathione S-transferases (GSTs) related disease26,27. Through con-
jugating glutathione with free radical scavengers and facilitating their elimination from the body to reduce poten-
tial toxicities of target substances28, GSTs comprise a superfamily of detoxification enzymes that are encoded in 
two main genes: the GSTM1 gene on chromosome 1p13.3, which encodes for cytosolic GST class Mu 1 enzyme, 
and the GSTT1 gene on chromosome 22q11.2, which encodes for cytosolic GST class theta 1 enzyme29,30. Both 
GSTM1 and GSTT1 may harbor a null mutation comprising a complete deletion of the respective gene via une-
qual homologous crossover, and homozygous null mutations can lead to a variable, tissue-specific loss of GSTs 
activity31.
GSTM1 is mainly expressed in the liver and brain32, a fact that supports the significant associations observed 
between this gene and both ATDH and SCZ. Furthermore, GSTM1 not only detoxifies the toxic metabolites 
of anti-TB drugs generated by CYP2E1 in the liver, but also catalyzes the conjugation of glutathione with ami-
nochrome and dopa-o-quinone metabolites of oxidized dopamine in the brain32. Reactive oxygen species are 
generated at high rates in the brain, and regulation of the growth and pruning of neurons is partly attributed to 
the redox mechanism that controls the balance between neuro destructive oxidants and neuro protective anti-
oxidants33. Therefore, GSTM1 inactivation due to the GSTM1 null genotype not only causes liver injury but also 
promotes the accumulation of neuro destructive oxidants and consequent development of SCZ (Fig. 3).
Compared with our previous study10, the present study exhibits the following improvements: (1) the current 
meta-analysis or field synopsis is more compressive and systematic and involves as many candidate genes as possi-
ble including GST genes; (2) the current analysis is updated regularly using the online database ATDH-SCZgenes; 
and (3) more strict statistical methods were used in this analysis, including ORs instead of risk ratios and a 
threshold P value for publication bias of 0.1 instead of 0.05. However, this study also has some limits, including 
use of the STRING database, a functional association network without direction. The availability of a disease 
specific directed network might lead to more comprehensive and concrete conclusions using the current method. 
Figure 3. Schematic illustration of the roles of GSTM1 in liver and brain. INH, isoniazid; RIF, rifampin; 
PZA, pyrazinamide; NAT2, arylamine N-acetyltransferase2; CYP2E1, cytochrome P450 2E1.
www.nature.com/scientificreports/
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Additionally, the significant association of GSTM1 with SCZ should be interpreted with caution, as the P value 
for the publication bias test was 0.0637; this value represents the evidence of small-study effects with all studies 
included. However, our sensitivity analysis to assess the effects of individual studies on the overall meta-analysis 
estimate yielded P values for overall effects of 0.001–0.015 in the GSTM1 and SCZ analysis, indicating the stability 
of positive results obtained with these analyses. Furthermore, till now, no GWASs on ATDH have been reported 
and the number of reported ATDH-associated genes is small; therefore, only GSTM1 and GSTT1 genes could be 
validated in the current systemic meta-analysis. Validation of other causal genes must be performed in future 
studies.
In summary, we provide a list of possible causal genetic factors associated with both ATDH and SCZ, and have 
identified a shared genetic basis of these two diseases. Furthermore, we have created and will regularly update the 
ATDH-SCZgenes online database to validate the association of each candidate gene with either disease. Finally, 
GSTM1 was validated as a causal factor of both ATDH and SCZ, whereas other genes such as CYP2E1 and DRD2 
will require further validation.
Methods
Ethics statement. The current research was performed in compliance with the Helsinki Declaration and 
was approved by the Bioethics committee of the Bio-X Institutes of Shanghai Jiaotong University. Informed con-
sent was obtained from all subjects.
Network-based analysis. All known ATDH/ATDILI- and SCZ-related genes reported (including GWAS) 
to have significant effects on the relative disease by at least one study were collected using GenBank (http://www.
ncbi.nlm.nih.gov/gene/), and are listed in Supplementary Table S1. These genes were used as seed genes in the 
subsequent analysis. To explore the causal factors of ATDH and SCZ, a novel network-based analysis pipeline was 
developed per the workflow shown in Fig. 4. First, established seed genes related to ATDH or SCZ, were mapped 
onto the highest confidence human STRING network (version 9.1, confidence score > 0.900), which included a 
total of 8,823 genes34. These seed genes were subsequently expanded on the network using the RWR method35 
as follows: a PPI network G = (V, E) comprised of a set of proteins V and a set of interactions E is represented by 
an n × n adjacency matrix A, where n is the number of proteins. The entries at row i and column j are set to 1 if 
Figure 4. Identification of the key drivers of both ATDH and SCZ. (A) Known ATDH and SCZ genes were 
mapped onto the STRING network. (B) ATDH genes were expanded using RWR and the known ADTH genes 
as seed genes. The stop point was determined using a running sum curve reflective of the overlap between  
the top expanded ATDH genes and known SCZ genes. SCZ genes were expanded in a similar manner.  
(C) Common genes between ATDH and SCZ were highlighted for further key driver evaluation. (D) The 
neighbor genes of candidate key drivers were tested for overlap significance with common disease genes. These 
neighbors of key drivers should significantly affect the more common disease genes.
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protein i interacts with protein j; otherwise they are set to 0. First, the adjacency matrix A was normalized in a 
column-wise maner as follows
′ =
∑ =
A
A
A (1)
i j
i j
k
n
k j
[ , ]
[ , ]
1 [ , ]
The random walker initiates at a set of seed genes, (e.g., known disease genes). The initial state P0 can be formu-
lated as a column vector
ψ ψ ψ ψ=  P [ ] (2)i n
T
0 1 2
where ψi is set to 1/m for m seed genes and to 0 for the other genes on the network, and n is the number of genes 
on the network. The random walker randomly visits the adjacent genes for every t → t + 1. The state probabilities 
Pt+1 at time t + 1 are calculated as follows
= − ′ ++P r A P rP(1 ) (3)t t1 0
where Pt represents the state probabilities at time t, r is the restart probability (i.e., starting from the seed genes 
again), which was set to 0.7 as suggested by multiple previous studies36–41. This process was repeated until a 
steady-state was reached; this was defined as a difference between two steps of < 1e-6 according to previous 
studies38,42,43.
After expansion, all genes on the network were assigned disease gene probability. To determine the boundaries 
of gene expansion, we developed a new idea from GSEA and calculated the running sum from the top to bottom 
of the ranked gene list. Specifically, when we expanded ATDH genes from the ATDH seed genes, all genes on the 
network were ranked according to the likelihood of being an ATDH-related gene. If we encountered a gene that 
was not an established SCZ seed gene, −
−
G
N G
 was added to the running sum, where N is the number of all 
network genes and G is the number of known established SCZ seed genes; otherwise, −N G
G
 was added44,45. 
Based on the running sum, a peak of network expansion from the ATDH seed genes was determined. This cutoff 
was then used to obtain a list for ATDH seed gene expansion. A list for SCZ seed gene expansion was generated 
similarly. Common genes between these two lists (i.e., overlapped genes) were studied because these might more 
robustly reflect the common genetic basis of the two diseases. Finally, we screened all possible causal gene factors 
by testing their neighbors for overlapped genes using the hypergeometric test P value46.
∑=
−
−
=
( )( )
( )
p
M
k
N M
n k
N
n (4)k m
n
where N is the number of all network genes, M is the number of common disease genes, n is the number of 
neighbor genes, and m is the number of neighbor genes that are common disease genes. To control the FDR, 
hypergeometric test P values were adjusted according to the method published by Benjamini & Hochberg47. 
The analysis was conducted using R software version 3.1.2 and RWR code was obtained from RWOAG package 
(https://r-forge.r-project.org/R/?group_id= 1126).
Literature search. The digital medical databases PubMed, Scopus, ISI Web of Science, EMBASE, Chinese 
National Knowledge Infrastructure(CNKI) and the Chinese BioMedical Literature Database were searched for 
studies with publication dates up to 03/31/2016 using the following keywords: (“anti-tuberculosis drug-induced 
liver injury”, “anti-tuberculosis drug-induced hepatotoxicity”, “ATDH” or “ATDILI”) and (“Schizophrenia”), 
together with the full name or abbreviation of each candidate causal gene, including: “cytochrome P4502E1”, 
“CYP2E1”, “UDP-glucuronosyltransferase 1A6”, “UGT1A6”, “glutathione S-transferaseM1”, “GSTM1”, and “glu-
tathione S-transferase T1” or “GSTT1”. The references of retrieved articles were also reviewed to identify addi-
tional relevant literatures.
Inclusion and exclusion criteria. Articles included in the meta-analysis complied with the following 
criteria: (1) original case-control association studies based on randomly selected individuals; (2) Provision of 
complete genotype distribution data; (3) cases comprising TB patients with ATDH and controls comprising TB 
patients without ATDH or (4) cases comprising SCZ patients and controls comprising healthy subjects; and (5) 
at least three available studies regarding the association of each gene with either disease. Other studies, such 
as case-only studies, duplications, animal studies, comparisons of laboratory methods, editorials, and review 
articles were excluded. Studies were further evaluated using the Quality-Evaluation Score Sheet16 (version 2.0) 
(Supplementary Table S2); a score of 8–10 indicated a high quality study.
Data extraction. Data extraction was performed independently by two reviewers using a standardized pro-
tocol and reporting form. Discrepancies between the two reviewers were resolved by further discussion with a 
third party. For overlapping studies, the study with the larger sample size was retained for the meta-analysis. The 
recorded study characteristics included: (1) the first author’s name, (2) publication year, (3) sample ethnicity, (4) 
control and case characteristics, (5) methods used for genotyping and (6) target genes.
Statistical analysis. The strengths of the associations between gene polymorphisms and the risk of ATDH 
or SCZ were measured using ORs with corresponding 95% CIs. Pooled ORs were calculated for null vs. present 
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genotype camparisons. If the total number of studies was < 20, the random-effect model of meta-analysis was 
used to calculate the pooled ORs according to the DerSimonian–Laird method; if the number was ≥ 20, the 
fixed-effect model was applied according to the Mantel-Haenszel method48,49. Inter-study heterogeneity was 
assessed using the chi-square-based Q-test (Cochran’s Q statistic), and a strict P value < 0.1 was considered sta-
tistically significant14.
The I2 values = ×−( )( )I 100%2 Q dfQ  and corresponding 95% CIs were also calculated to describe the per-
centages of variability in the effect estimates that were attributable to heterogeneity rather than sampling error, an 
I2 > 50% was roughly considered to indicate substantial heterogeneity50. This formula use Q as well as degrees of 
freedom50,51. A sensitivity analysis, in which one study at a time was removed prior to analysis, was conducted to 
evaluate whether a single study would significantly affect the results. This analysis used a model other than the 
model used to calculate the pooled ORs. Harbord’s test was used to test small-study effects among which publica-
tion bias might be a contributor, and a P value < 0.1 was considered representative of statistically significant 
publication bias52. All statistical analyses were implemented in Review Manger 5.2 (The Nordic Cochrane Centre, 
Copenhagen, Denmark) and Stata version 11.2 (Stata Corporation, College Station, TX, USA).
Credibility of meta-analysis results. A power analysis was performed using the Power and Sample Size 
Program with α = 0.05 as the level of significance; effects sizes were estimated from the meta-analyses19. To assess 
the noteworthiness of an association, the FPRP34 was estimated using a FPRP threshold of 0.2 and prior proba-
bilities of 0.05–10−6. Cumulative evidence for genetic associations of GSTM1 and GSTT1 present genotypes with 
ATDH and SCZ, respectively, were assessed according to the Venice interim criteria, which include the amount 
of evidence, replication of results and protection from bias22. Regarding the amount of evidence, grades of A, B, 
and C were given for a nminor > 1,000, 100–1,000 and < 100, respectively, where nminor refers to the total number 
of cases and controls with the least frequent genotype. Regarding replication, grades A, B, and C were given for 
I2 values < 25%, 25–50% and > 50%, respectively. Regarding protection from bias, any of the following criteria 
should be met: (1) combined OR of 0.87–1.15; (2) high genotyping quality with a low genotyping error rate; (3) 
retained statistical significance after excluding the first published study; or (4) no evidence of small-study effects 
according to a Harbord regression test (significance: P < 0.0553).
Data accessibility. The datasets supporting this article have been uploaded as part of the Supplementary 
Material.
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